Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.95
+0.18001.41%
Post-market: 12.950.00000.00%16:37 EDT
Volume:961.33K
Turnover:12.33M
Market Cap:2.10B
PE:587.61
High:12.97
Open:12.77
Low:12.66
Close:12.77
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:0.76
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:8.70
PE(LYR):291.69

Loading ...

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
2 hours ago

Vertex Pharmaceuticals to present data on Alyftrek at NACFC

TIPRANKS
·
5 hours ago

Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors

TIPRANKS
·
6 hours ago

Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants

TIPRANKS
·
Yesterday

Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000

Dow Jones
·
Yesterday

Vertex Files Form 3 Initial Beneficial Ownership Statement for Director Debanjan Saha

Reuters
·
Yesterday

Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital

TIPRANKS
·
Oct 08

RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

Vertex Minerals lodges 2026 corporate governance statement with ASX

TIPRANKS
·
Oct 02

Vertex adds AI-focused independent director to board

TIPRANKS
·
Oct 02

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Vertex appoints Saha to Board of Directors

TIPRANKS
·
Oct 01

Vertex Appoints Datarobot CEO Debanjan Saha to Board of Directors

THOMSON REUTERS
·
Oct 01

Press Release: Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors

Dow Jones
·
Oct 01

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23